Tick-Borne Illnesses Treatment Guidelines
Introduction to Treatment
- For patients with ehrlichiosis or anaplasmosis who have a documented severe allergy to doxycycline, rifampin is the only acceptable alternative treatment, administered at 300 mg orally twice daily for adults or 10 mg/kg twice daily for children (maximum 300 mg per dose) for 7-10 days, as recommended by the Centers for Disease Control and Prevention (CDC) 1
- Doxycycline is the preferred treatment for anaplasmosis, with a recommended dosage of 100 mg orally twice daily for 10 days in adults, and 4 mg/kg per day divided into two doses for children, with a maximum of 100 mg per dose, as recommended by the American Academy of Pediatrics and CDC 1, 2
Diagnosis and Treatment Considerations
- Determine the severity and nature of the doxycycline allergy: for non-life-threatening reactions, consider administering doxycycline in an observed setting after risk-benefit evaluation, while for life-threatening allergies, proceed to alternative therapy, and consider allergy/immunology consultation for possible doxycycline desensitization in critical cases, according to the CDC 1
- Rule out Rocky Mountain Spotted Fever (RMSF) before initiating rifampin, as rifampin is NOT effective against RMSF, and be aware that rifampin does not effectively treat potential co-infection with Borrelia burgdorferi (Lyme disease), as stated by the CDC 1
- If coinfection with B. burgdorferi is suspected, treatment should be extended to 10 days or additional treatment with an antimicrobial effective against Lyme disease should be added, such as amoxicillin or cefuroxime axetil 1, 2
Ineffective Antimicrobials
- The following antimicrobials are ineffective against Ehrlichia and Anaplasma and should NOT be used:
- Sulfonamide antimicrobials can increase disease severity and should be avoided, according to the CDC 1 and the American Academy of Pediatrics 3
Special Populations
- Rifampin may be considered as an alternative for pregnant women with ehrlichiosis or anaplasmosis, although the CDC does not provide specific guidance on this topic, it is essential to consider the risks and benefits, with a recommended dosage of 300 mg orally twice daily for 7-10 days 1, 2
- Rifampin has been used successfully in children with related tick-borne infections, and immunocompromised patients require close monitoring regardless of treatment choice, as stated by the CDC 1
Treatment Outcomes and Monitoring
- Fever typically subsides within 24-48 hours after initiating doxycycline treatment, and lack of clinical response within 48 hours should prompt consideration of alternative diagnoses or possible coinfection, with severely ill patients potentially requiring more than 48 hours of treatment before clinical improvement is noted, according to the CDC 1
- Patients with evidence of organ dysfunction, severe thrombocytopenia, mental status changes, or inability to take oral medications reliably require close monitoring and supportive therapy, as recommended by the CDC 1
- Close follow-up is essential for patients treated as outpatients, with monitoring for resolution of clinical and laboratory abnormalities, especially in patients treated with rifampin, according to the CDC 1, 2
Complications and Coinfections
- Complications of anaplasmosis can include shock, organ dysfunction, and rarely death, emphasizing the importance of prompt and effective treatment, according to the CDC 1
- Coinfection with B. burgdorferi has been reported in up to 10% of patients with Lyme disease, and if suspected or confirmed in patients receiving rifampin for anaplasmosis, additional treatment with amoxicillin or cefuroxime axetil is necessary, as recommended by the CDC 1, 2
- Early treatment is critical, as delay in treatment of tickborne rickettsial diseases can lead to severe disease and death, with mortality less than 1% with appropriate treatment, according to the CDC 1